Novel glucose-lowering drugs for non-alcoholic fatty liver disease

doi:10.4239/wjd.v12.i1.84

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7125)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

477

WORD

207

HTML

3266

Figures (1-2)

221

Tables (1-5)

233

Sum=4404

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

443

Download

891

Sum=1334

Publishing Process of This Article

Item

Count

Browse

491

Download

896

Sum=1387

Jan 15, 2021 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Diabetes. Jan 15, 2021; 12(1): 84-97
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.84

Table 4 Comparison of magnetic resonance imaging proton density fat fraction and visceral fat area change from baseline in different treatment groups

	Studies	Participants	WMD	95%CI		P value
MRI-PDFF change
DPP-4 inhibitors	2	52/49	-2.31	-4.92	0.29	0.08
GLP-1 RAs	1	24/24	-3.20	-5.98	-0.42	0.02
SGLT2 inhibitors	2	65/61	-1.18	-2.38	0.03	0.06
VFA change
DPP-4 inhibitors	1	27/24	-23.10	-38.84	-7.36	0.004
GLP-1 RAs	1	24/24	-30.40	-46.86	-13.94	0.0003
SGLT2 inhibitors	2	48/50	-23.48	-25.85	-21.12	< 0.0001

MRI-PDFF: Magnetic resonance imaging proton density fat fraction; VAF: Visceral fat area; WMD: Weighted mean difference; CI: Confidence interval; DPP-4: Dipeptidyl peptidase-4; GLP-1 RA: Glucagon-like peptide-1 receptor agonist; SGLT2: Sodium-glucose cotransporter 2.

Citation: Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97
URL: https://www.wjgnet.com/1948-9358/full/v12/i1/84.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i1.84